BACKGROUND: Animal studies suggest that ischemic preconditioning prolongs coagulation times. OBJECTIVE: Because coagulation changes could hinder the translation of preconditioning into clinical settings where hemorrhage may be an issue, such as ischemic or hemorrhagic stroke, we evaluated the effects of remote ischemic preconditioning (RIPC) on coagulation in patients undergoing RIPC after aneurysmal subarachnoid hemorrhage (SAH). METHODS: Twenty-one patients with SAH (mean age, 56.3 years) underwent 137 RIPC sessions 2 to 12 days after SAH, each consisting of 3 to 4 cycles of 5 to 10 minutes of lower limb ischemia followed by reperfusion. Partial thromboplastin time (PTT), prothrombin time (PT), and international normalized ratio (INR) were analyzed before and after sessions. Patients were followed for hemorrhagic complications. RESULTS: No immediate effect was identified on PTT (mean pre-RIPC, 27.62 s; post-RIPC, 27.54 s; P = .82), PT (pre-RIPC, 10.77 s; post-RIPC, 10.81 s; P = .59), or INR (pre-RIPC, 1.030; post-RIPC, 1.034; P = .57) after each session. However, statistically significant increases in PT and INR were identified after exposure to at least 4 sessions (mean PT pre-RIPC, 11.33 s; post-RIPC, 12.1 s; P = .01; INR pre-RIPC, 1.02; post-RIPC, 1.09; P = .014, PTT pre-RIPC, 27.4 s; post-RIPC, 27.85 s; P = .092) with a direct correlation between the number of sessions and the degree of increase in PT (Pearson correlation coefficient = 0.59, P = .007) and INR (Pearson correlation coefficient = 0.57, P = .010). Prolonged coagulation times were not observed in controls. No hemorrhagic complications were associated with the procedure. CONCLUSION: RIPC by limb ischemia appears to prolong the PT and INR in human subjects with SAH after at least 4 sessions, correlating with the number of sessions. However, values remained within normal range and there were no hemorrhagic complications.
BACKGROUND: Animal studies suggest that ischemic preconditioning prolongs coagulation times. OBJECTIVE: Because coagulation changes could hinder the translation of preconditioning into clinical settings where hemorrhage may be an issue, such as ischemic or hemorrhagic stroke, we evaluated the effects of remote ischemic preconditioning (RIPC) on coagulation in patients undergoing RIPC after aneurysmal subarachnoid hemorrhage (SAH). METHODS: Twenty-one patients with SAH (mean age, 56.3 years) underwent 137 RIPC sessions 2 to 12 days after SAH, each consisting of 3 to 4 cycles of 5 to 10 minutes of lower limb ischemia followed by reperfusion. Partial thromboplastin time (PTT), prothrombin time (PT), and international normalized ratio (INR) were analyzed before and after sessions. Patients were followed for hemorrhagic complications. RESULTS: No immediate effect was identified on PTT (mean pre-RIPC, 27.62 s; post-RIPC, 27.54 s; P = .82), PT (pre-RIPC, 10.77 s; post-RIPC, 10.81 s; P = .59), or INR (pre-RIPC, 1.030; post-RIPC, 1.034; P = .57) after each session. However, statistically significant increases in PT and INR were identified after exposure to at least 4 sessions (mean PT pre-RIPC, 11.33 s; post-RIPC, 12.1 s; P = .01; INR pre-RIPC, 1.02; post-RIPC, 1.09; P = .014, PTT pre-RIPC, 27.4 s; post-RIPC, 27.85 s; P = .092) with a direct correlation between the number of sessions and the degree of increase in PT (Pearson correlation coefficient = 0.59, P = .007) and INR (Pearson correlation coefficient = 0.57, P = .010). Prolonged coagulation times were not observed in controls. No hemorrhagic complications were associated with the procedure. CONCLUSION: RIPC by limb ischemia appears to prolong the PT and INR in human subjects with SAH after at least 4 sessions, correlating with the number of sessions. However, values remained within normal range and there were no hemorrhagic complications.
Authors: Kendra M Cherry-Allen; Jeff M Gidday; Jin-Moo Lee; Tamara Hershey; Catherine E Lang Journal: J Mot Behav Date: 2016-10-12 Impact factor: 1.328
Authors: Sebastian Koch; David Della-Morte; Kunjan R Dave; Ralph L Sacco; Miguel A Perez-Pinzon Journal: J Cereb Blood Flow Metab Date: 2014-03-19 Impact factor: 6.200
Authors: Diana A Gorog; Mohamed Farag; Nikolaos Spinthakis; Derek M Yellon; Hans Erik Bøtker; Rajesh K Kharbanda; Derek J Hausenloy Journal: Cardiovasc Res Date: 2021-01-21 Impact factor: 10.787
Authors: Selma Tülü; Miriam Mulino; Daniel Pinggera; Markus Luger; Philipp Würtinger; Astrid Grams; Thomas Bodner; Ronny Beer; Raimund Helbok; Raffaella Matteucci-Gothe; Claudia Unterhofer; Elke Gizewski; Erich Schmutzhard; Claudius Thomé; Martin Ortler Journal: Trials Date: 2015-12-29 Impact factor: 2.279
Authors: Md Nasrul Hoda; Susan C Fagan; Mohammad B Khan; Kumar Vaibhav; Aizaz Chaudhary; Phillip Wang; Krishnan M Dhandapani; Jennifer L Waller; David C Hess Journal: Exp Transl Stroke Med Date: 2014-10-09
Authors: Kumar Vaibhav; Molly Braun; Mohammad Badruzzaman Khan; Sumbul Fatima; Nancy Saad; Adarsh Shankar; Zenab T Khan; Ruth B S Harris; Qiuhua Yang; Yuqing Huo; Ali S Arbab; Shailendra Giri; Cargill H Alleyne; John R Vender; David C Hess; Babak Baban; Md Nasrul Hoda; Krishnan M Dhandapani Journal: J Exp Med Date: 2018-09-06 Impact factor: 14.307